Eloralintide

What It Is

Eloralintide (LY3841136) is a novel, selective amylin receptor agonist developed by Eli Lilly for the treatment of obesity. Unlike GLP-1 receptor agonists, eloralintide works through a distinct amylin-based mechanism — amylin is a peptide hormone co-secreted with insulin that promotes satiety and slows gastric emptying. In a 48-week Phase 2 multicenter, double-blind, randomized, placebo-controlled trial published in The Lancet, all treatment arms met the primary endpoint, demonstrating dose-dependent weight reductions from 9.5% to 20.1% compared to 0.4% with placebo. Notably, eloralintide demonstrated 11.3% additional weight loss when added to tirzepatide therapy, suggesting strong combination potential. The safety profile was favorable, with mild-to-moderate gastrointestinal events and fatigue as the most common adverse effects. Lilly's Phase 3 clinical studies are actively enrolling, and a Phase 2 combination trial with CT-388 is underway. The Phase 1 proof-of-concept study was formally published in Diabetes, Obesity and Metabolism (Bhattachar et al., 2026), confirming selective amylin receptor engagement and dose-proportional pharmacokinetics that support the ongoing Phase 3 program. Eloralintide represents a new drug class for obesity — selective amylin agonists — distinct from the GLP-1 and GIP agonists that currently dominate the market, and its combination potential may set a new efficacy ceiling for metabolic therapies. June 2026 update: following the ADA 2026 Scientific Sessions (June 5–8, New Orleans), eloralintide is increasingly viewed as the lead asset validating selective amylin agonism as a standalone obesity mechanism. Eli Lilly is running a dedicated Phase 2 trial of eloralintide alone and in combination with tirzepatide (NCT06916065), with analysts expecting combination data in late 2026, and the company has stated Phase 3 enrollment for eloralintide monotherapy will begin by the end of 2026. Industry analysts highlight eloralintide's notably milder gastrointestinal side-effect profile versus GLP-1 receptor agonists as its key differentiator — positioning it both as an alternative for GI-intolerant patients and as a 'reusable building block' in Lilly's combination strategy alongside tirzepatide and retatrutide.

Regulatory Status

Why Researchers Study It

Eloralintide represents a new class of obesity therapeutics — selective amylin receptor agonists — offering a GLP-1-independent mechanism. Its distinct pathway makes it a prime candidate for combination therapy with GLP-1 agonists, potentially achieving greater weight loss than either mechanism alone. The amylin pathway's role in satiety signaling and gastric emptying is complementary to GLP-1 effects.

Proposed Mechanisms

• Selectively activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and hypothalamus
• Promotes satiety through central appetite suppression via amylin signaling
• Slows gastric emptying to prolong post-meal fullness
• Does not directly engage GLP-1, GIP, or glucagon receptors — independent mechanism of action
• Long-acting design enables once-weekly subcutaneous dosing

Evidence Snapshot

Commonly Discussed Benefits

Safety & Cautions

Comparisons

See how Eloralintide compares to related peptides:

Calculator Tools

Use our research tools to explore dosing and reconstitution data:

Citations

1. [1] Eloralintide Phase 2 trial — Lancet 2025 PubMed
2. [2] Eli Lilly — Eloralintide Phase 2 results press release PubMed
3. [3] Eloralintide Phase 1 proof of concept — PMC PubMed
4. [4] Bhattachar SN. et al. — Eloralintide, a selective long-acting amylin receptor agonist: Phase 1 proof of concept (DOM 2026) PubMed
5. [5] ClinicalTrials.gov — Eloralintide and Eloralintide With Tirzepatide in Overweight or Obesity (NCT06916065) PubMed
6. [6] BioSpace — Obesity Space Abuzz With Oral, Amylin Assets as Momentum Rides Into 2026 PubMed
7. [7] Eli Lilly — What to know about eloralintide PubMed

Related Peptides